In a region where rare diseases have long outpaced the reach of public health systems, Singapore has taken a quiet but consequential step: becoming the first ASEAN nation to subsidize vutrisiran, a gene-silencing therapy for transthyretin amyloidosis, a disease that progressively destroys the heart and nerves. Beginning September 2026, eligible patients may have up to 75 percent of treatment costs covered through the government's Medication Assistance Fund, a decision grounded in clinical trial evidence showing meaningful reductions in mortality and disease progression. The move raises a quest
Singapore First in ASEAN to Subsidize Vutrisiran for Rare Amyloidosis
Patients with transthyretin amyloidosis, a progressive fatal disease with median survival of 2.6-5.8 years for cardiomyopathy cases, gain improved access to disease-modifying treatment through government subsidy.